⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 12, 2024Journal of Nuclear Medicine

Quantitative SPECT/CT Metrics in Early Prediction of [¹⁷⁷Lu]Lu-DOTATATE Treatment Response in Gastroenteropancreatic Neuroendocrine Tumor Patients

Onur Tuncer Daniel Steinberger Joseph R. Steiner Madeleine Hinojos Stephanie Y Rhee Brad Humphrey Farhad Mohammad Jafari Zuzan Caycı

View at Publisher

Ask AI

Bookmark

Share

Abstract

Our objective is to explore quantitative imaging markers for early prediction of treatment response in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) undergoing [

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Tuncer et al. (2024) studied this question.

synapsesocial.com/papers/68e58a69b6db643587526bd0 https://doi.org/10.2967/jnumed.124.267964

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Absorbed Dose–Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [<sup>177</sup>Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine2024 · 60 citations
2Relationship Between Absorbed Dose and Response in Neuroendocrine Tumors Treated with [<sup>177</sup>Lu]Lu-DOTATATE2024 · 38 citations
3Relationship between absorbed dose and SUV derived from SPECT/CT imaging and dose-response in patients with neuroendocrine tumors treated with [¹⁷⁷Lu]Lu-DOTA-TATEOriginal Research · 2026
4Safety and time to response of [<sup>177</sup>Lu]Lu-DOTATATE in patients with newly diagnosed advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Sub-analysis of the phase 3 randomized NETTER-2 study.2024 · 2 citations
5Pharmacokinetics and Dosimetry of <sup>177</sup> Lu-DOTATATE in Patients with Advanced Well-Differentiated, Gastroenteropancreatic Neuroendocrine Tumors: Results from a Substudy of the Phase 3 XT-XTR008-3-01 TrialLate-Phase Clinical Trial · 2026 · 1 citations

More related papers

Semiquantitative SSTR PET metrics show molecular–morphologic discordance after 177Lu-DOTATATE in gastroenteropancreatic neuroendocrine neoplasms: an exploratory paired target-lesion analysis2026
Long-term clinical outcomes of [177Lu]Lu-DOTATATE in patients with metastatic neuroendocrine tumors2024
177Lu-DOTATATE PRRT Safety and Organ-at-Risk Dosimetry in Patients With Gastroenteropancreatic Neuroendocrine Tumors2024

More from Journal of Nuclear Medicine

PSMA PET Evaluation with a Deep Learning Platform Compared with a Standard Image Viewer and HistopathologyThu,
¹⁸F-FDG PET Reveals Voxel-Based Decreases in Brain Glucose Uptake After Chemotherapy in Leukemia Patients: A Retrospective Matched-Control StudyThu,